Aurobindo Pharma acquires Khandelwal Laboratories Pvt

Aurobindo Pharma Limited has acquired the non-oncology prescription portfolio of Mumbai-based Khandelwal Laboratories Private Limited. The transaction, executed through Auro Pharma Limited, a wholly owned subsidiary of Aurobindo Pharma, is valued at ₹325 crore and was finalized effective January 1, 2026.

The acquisition involves 23 established brands marketed across 67 stock-keeping units, along with nine products in development. Key therapeutic areas include anti-infective and pain management segments, sectors in which Aurobindo plans to expand its presence. Khandelwal Laboratories, which has operated since 1973, posted a turnover of ₹1,135.3 million for the financial year 2024-25, with EBITDA standing at ₹289.9 million, signaling a viable and potentially lucrative addition to Aurobindo’s business.

The deal expands Aurobindo’s presence in the domestic pharmaceutical market by leveraging Khandelwal's established distribution network of over 1,600 stockists and a workforce comprising approximately 470 field staff members. This infrastructure enhancement offers Aurobindo immediate market access and underscores the company's strategy to enrich its portfolio and boost its competitive footing.

As the broader Indian pharmaceutical market continues to grow, the acquisition strengthens Aurobindo's operational base within the country, reflecting the company’s intent to cater to increasing domestic demand. The move adds heft to the company's product offerings and positions it more robustly against competitors in the heavily scrutinized anti-infective and pain management spaces.

The transaction has been structured without transferring certain assets, such as intellectual property and inventories, suggesting a focus on swiftly integrating Khandelwal’s brands and market reach into Aurobindo’s existing operations. The market reacted positively, with shares of Aurobindo Pharma closing up by 1.18% at ₹1,197 on the National Stock Exchange of India. The acquisition marks a tactical expansion as Aurobindo aligns itself with evolving pharmaceutical needs in India.